peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical development partner Axis-Shield Diagnostics launches CE-marked ELISA assay for measurement of HBP

18 Dec 2012, 08:10
Regulatory information

The Hansa Medical development partner Axis-Shield Diagnostics has launched a CE-marked ELISA assay for measurement of Heparin Binding Protein, HBP. For more information on the assay, please visit

HBP is a new marker that has been shown to be useful in identifying patients on admission to the Emergency Department who are at risk of developing severe sepsis. Sepsis is the body's systemic inflammatory response to infection and can progress to severe sepsis, septic shock and ultimately multiple organ failure. Early diagnosis and appropriate treatment of severe sepsis is vital to improve the patient's chance of survival.

In 2009, Hansa Medical entered a collaboration and license agreement with Axis-Shield Diagnostics to further develop the Hansa Medical prototype HBP-assay (HMD-301) and subsequently launch a commercial assay.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoS and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.